View live charts, options flow & technicals for Medtronic plc →
Open Dashboard
Medtronic plc (MDT) is a healthcare company in the medical devices industry with $37.54B in trailing revenue trading at a 22.4× trailing P/E — analyst consensus: buy.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Key Statistics
Market Cap
$114.23B
Revenue (TTM)
$37.54B
EPS (TTM)
$3.99
EPS (Fwd est.)
$6.41
Employees
95,000
Trailing P/E
22.38
Forward P/E
13.94
PEG Ratio
1.63
Price / Sales
3.04
Price / Book
2.28
EV / EBITDA
12.89
Beta (5Y)
0.57
Analyst Consensus
Consensus
Buy
Analyst Price Target
+17.4% upside
Target: $104.83
Annual Revenue & Net Income
RevenueNet Income
'23
$31.23B
$3.76B
'24
$32.36B
$3.68B
'25
$33.54B
$4.66B
'26
$36.36B
$4.80B
Earnings History
Quarter
Actual EPS
Estimate
Result
Sep 2026
$1.45
$1.39
Beat (+4.5%)
Jun 2026
$1.55
$1.54
Beat (+0.6%)
Feb 2026
$1.36
$1.34
Beat (+1.9%)
Nov 2025
$1.36
$1.31
Beat (+3.5%)
Next Earnings Report
Medtronic plc is next expected to report earnings on 17 Nov 2026.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverte…
What is MDT's market cap?
Medtronic plc has a market capitalization of approximately $114.23B.
What is MDT's P/E ratio?
Medtronic plc trades at a trailing P/E ratio of 22.4x and a forward P/E of 13.9x, which is below the broad market average of ~25x.
How much revenue does MDT generate?
Medtronic plc generated $37.54B in trailing 12-month revenue.
What do analysts say about MDT?
The analyst consensus rating for Medtronic plc is buy, with a mean price target of $104.83. That implies +17.4% upside from the current price.
When does MDT report earnings?
Medtronic plc is next scheduled to report earnings on 17 Nov 2026.
Does MDT pay a dividend?
Yes. Medtronic plc pays a dividend with a current yield of 3.17%, at an annual rate of $2.88 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Medtronic plc on Apsis Markets.